Skip to main content
Publications
Beier L, Lu S, Franca LR, Marler S, Lip GYH, Huisman MV, Teutsch C, Halperin JL, Zint K, Diener HC, Baker L, Ma CS, Paquette M, Bartels DB, Dubner SJ, Lyrer P, Senges J, Rothman KJ . Evolution of antithrombotic therapy for patients with atrial fibrillation: the prospective global GLORIA-AF registry program . PLoS One. 2022 Oct 6;17(10):e0274237. doi: 10.1371/journal.pone.0274237
Gold BD, Goodwin B, Davis K, Sweeney C , Reynolds M , Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Treatment burden and associated costs in adolescents and adults with eosinophilic esophagitis in the USA . Poster presented at the AMCP Nexus 2021; October 19, 2021. [abstract] J Manag Care Pharm. 2021 Oct; 27(10-a):S82.
Huang L, Bommireddy R, Munoz LE, Guin RN, Wei C, Ruggieri A, Menon AP , Li X, Shanmugam M, Owonikoko TK, Ramalingam SS, Selvaraj P. Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor . PLoS One. 2021 Aug 19;16(8):e0254125. doi: 10.1371/journal.pone.0254125
Koziel M, Teutsch C, Halperin JL, Rothman KJ , Diener HC, Ma CS, Marler S, Lu S, Gurusamy VK, Huisman MV, Lip GYH, GLORIA-AF Investigators. Atrial fibrillation and comorbidities: clinical characteristics and antithrombotic treatment in GLORIA-AF . PLoS One. 2021 Apr 14;16(4):e0249524. doi: 10.1371/journal.pone.0249524
Bedard A, Carsin AE , Fuertes E, Accordini S, Dharmage SC, Garcia-Larsen V, Heinrich J, Janson C, Johannessen A, Leynaert B, Sanchez-Ramos JL, Peralta GP, Pin I, Squillacioti G, Weyler J, Jarvis D, Garcia-Aymerich J. Physical activity and lung function-cause or consequence? PLoS One. 2020 Aug 20;15(8):e0237769. doi: 10.1371/journal.pone.0237769
Fuertes E, Carsin AE , Garcia-Larsen V, Guerra S, Pin I, Leynaert B, Accordini S, Martinez-Moratalla J, Anto JM, Urrutia I, Le Gouellec A, Heinrich J, Gislason T, Jogi R, Janson C, Jarvis D, Garcia-Aymerich J. The role of C-reactive protein levels on the association of physical activity with lung function in adults . PLoS One. 2019 Sep 23;14(9):e0222578. doi: 10.1371/journal.pone.0222578
Peay H, Fischer R, Tzeng JP, Hesterlee SE, Morris C, Martin AS, Rensch C, Smith E, Ricotti V, Beaverson K, Wand H, Mansfield C . Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: a qualitative preference study of patients and parents . PLoS One. 2019 May 1;14(5):e0213649. doi: 10.1371/journal.pone.0213649
Bugner C, Vaccaro J, Schwab P , Cornett D, Drzayich Jankus D, Martinez Vasquez D, Harris J, Sethi M, Cole B. Real-world comparative effectiveness, safety, and health care costs of Sacubitril/ Valsartan versus Angiotensin-II receptor blockers in a Medicare population . Poster presented at the 2019 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 25, 2019. [abstract] J Manag Care Pharm. 2019 Mar; 25(3-a):S10.
Jia X, Zhao Y, Carrico J, Brodtkorb TH , Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States . Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):S78.
Jia X, Zhao Y, Carrico J, Brodtkorb TH , Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States . Poster presented at the 2018 AMCP NEXUS; October 22, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10a):S79.
Margulis AV , Linder M, Arana A , Pottegard A, Berglind IA, Bui CL , Kristiansen NS, Bahmanyar S, McQuay LJ, Atsma WJ, Appenteng K, D'Silva M, Perez-Gutthann S , Hallas J. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom . PLoS One. 2018 Sep 27;13(9):e0204456. doi: 10.1371/journal.pone.0204456